Novo Nordisk's $630M Volume Plunge to 151st Amid Lawsuit Over GLP-1 Risk Disclosures

On August 14, 2025, Novo Nordisk (NVO) traded with a volume of $0.63 billion, a 35.66% decline from the previous day, ranking 151st in market activity. The stock closed with a 0.10% gain, showing limited movement amid broader market dynamics.

A class-action lawsuit filed by Robbins LLP has drawn attention to Novo Nordisk’s market communications. The firm alleges that between May 7 and July 28, 2025, the company overstated its growth potential by failing to disclose risks related to compounded GLP-1 alternatives. Key concerns include misrepresentations about patient transition rates to branded products and an exaggerated assessment of the GLP-1 market size. These allegations emerged after Novo revised its 2025 sales and profit outlook on July 29, citing challenges from compounded GLP-1 usage and slower market adoption.

The litigation highlights potential governance issues and market transparency risks. Investors purchasing NVO shares during the specified period may qualify to participate in the case, with a September 30, 2025 deadline for lead plaintiff submissions. While the stock’s 0.10% rise on August 14 suggests limited short-term impact, the legal developments could influence long-term investor sentiment and regulatory scrutiny.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 generated a 0.98% average 1-day return. Over 365 days, the total return was 31.52%, reflecting mixed performance influenced by market volatility and timing risks. This underscores the challenges of relying on short-term momentum in equity strategies.